REGENXBIO, Inc. (RGNX)
7.20
+0.28
(+3.97%)
USD |
NASDAQ |
Oct 19, 12:21
REGENXBIO Cash from Operations (Annual) : -123.96M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -123.96M |
| December 31, 2024 | -173.12M |
| December 31, 2023 | -218.41M |
| December 31, 2022 | -207.49M |
| December 31, 2021 | 218.88M |
| December 31, 2020 | -54.06M |
| December 31, 2019 | -107.70M |
| Date | Value |
|---|---|
| December 31, 2018 | 104.65M |
| December 31, 2017 | -57.99M |
| December 31, 2016 | -48.56M |
| December 31, 2015 | -22.48M |
| December 31, 2014 | -2.399M |
| December 31, 2013 | -3.012M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| AbbVie, Inc. | 19.03B |
| United Therapeutics Corp. | 1.561B |
| Ardelyx, Inc. | -42.48M |
| Biomea Fusion, Inc. | -70.37M |
| RenovoRx, Inc. | -10.97M |